logo-loader
viewAdvanced Oncotherapy PLC

Launch of 2018 SAYE Scheme

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;font-weight:bold;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:70.9pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:106.3pt;text-align:justify;text-indent:-35.4pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:5.0cm;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:177.2pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}strong{font-family:"Times New Roman","serif";}em{font-family:"Times New Roman","serif";}p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}acronym{font-family:"Times New Roman","serif";} address{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-div:italic;}cite{font-family:"Times New Roman","serif";}code{font-family:Consolas;}dfn{font-family:"Times New Roman","serif";}samp{font-family:Consolas;}tt{font-family:Consolas;}var{font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .mt{size:595.3pt 841.9pt;margin:2.0cm 42.45pt 49.65pt 42.55pt;}div.mt{}p.nv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; text-align: center}span.nt{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.nw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: center}span.nr{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";}span.np{font-family:"Calibri","sans-serif"}p.nx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.no{font-family:"Calibri","sans-serif";color:black} p.ny{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}p.nz{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}span.oa{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.nk{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.ob{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.nj{font-family:"Calibri","sans-serif"; color:#0D0D0D}table.oc{width:489.05pt;margin-left:-12.5pt;border-collapse:collapse}td.ng{width:220.25pt;padding:0cm 5.4pt 0cm 5.4pt}p.od{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 7.1pt}td.nd{width:247.2pt;padding:0cm 5.4pt 0cm 5.4pt} p.oe{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: right}span.nf{font-size:10.0pt; font-family:"Calibri","sans-serif"}p.of{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";margin-left:7.1pt}span.nc{font-family: "Calibri","sans-serif"}p.og{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}span.oh{font-family:"Calibri","sans-serif";color:black}span.oi{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"; color:black}span.oj{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"}span.ok{font-family:"Times New Roman","serif";font-size:10.0pt}p.ol{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify; text-autospace: none} p.om{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";margin-bottom:8.0pt;line-height:107%}span.on{font-family:"Times New Roman","serif";font-family: "Calibri","sans-serif"; font-weight: bold}p.oo{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align:justify}span.mz{font-family:"Calibri","sans-serif"; color:black} /**/
RNS Number : 2691L
Advanced Oncotherapy PLC
21 December 2018
 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

 

Launch of 2018 SAYE Scheme

 

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, announces that it has invited employees to participate in the Company's 2018 SAYE Option Plan which was approved at the AGM in July 2018. This SAYE scheme is open to all employees with more than one month's service. Pursuant to this SAYE Option Plan, participants can make monthly contributions of up to £500 on a three-year savings account.

At the end of this three-year period, employees will have the option to acquire Ordinary Shares of 25 pence each ('Ordinary Shares') in the Company at 40 pence which is the same price as at the fund raise announced today, subject to the rules of the Scheme. The options will be exercisable for up to 6 months after the 3-year period has ended.

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / Edward Thomas

Tel: +44 20 7601 6100



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus

Mob: +44 7876 741 001 / +44 7980 541 893

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBGBDDDBDBGIB

Quick facts: Advanced Oncotherapy PLC

Price: 38

Market: LSE
Market Cap: £90.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17